Objective The study will explore effects of the autoantibodies against AT1 receptor and angiotensin Ⅱ on the refractory hypertension. Methods Seventy-seven patients (46 men and 31 women) with essential hypertension w...Objective The study will explore effects of the autoantibodies against AT1 receptor and angiotensin Ⅱ on the refractory hypertension. Methods Seventy-seven patients (46 men and 31 women) with essential hypertension were divided into groups of refractory hypertension (RH) and hypertension (HT) according to the 1999 WHO-ISH Guidelines for the Management of Hypertension. Forty normotensives (22 men) were recruited as controls. The mean age was 54. 3±13 years old in RH group, 53. 5±9 years old in HT group and 51. 2±11. 9 years old in normotensives (NT) group. The mean blood pressure was 154. 2±9. 4/98. 4± 8. 2 mmHg in RH group and 130. 1±7. 6/80. 5±6. 7 mmHg in HT group after combination drug therapy of hypertension for 4 weeks. Blood pressure in NT group was 120. 8±11. 7/76. 4 ± 7. 2 mmHg. The epitope of the 2nd extracellular loops of AT1 receptor was synthesized and used as antigens to screen the autoantibodies by ELISA. Plasma angiotensin (Ang) II were examined by a radioimmunoassay. Results The autoantibodies against AT1 receptor were positive in 18 (46. 15 %) patients with RH, in 4 (10. 5 % ) hypertension and in 3 (7. 5 % ) normotensives, P < 0. 01. Ang Ⅱwas 57. 01±52. 63 pmol/L in patients with RH. Both the autoantibodies positive and the Ang Ⅱ increasing were 4 (10. 3 % ) cases, both normal were 7 (17. 9 % ) cases, the autoantibodies positive or Ang II increasing was all of 14 (35. 9 % ) cases (x2 = 0. 09, P>0. 05) . There was no relationship between the autoantibodies against AT1 receptor and the angiotensin Ⅱ in refractory hypertension. Conclusion The autoantibodies against AT1 receptor and Ang Ⅱ might be two independent factors in developing of refractory hypertension. The findings suggest that AT1 receptor an-tagnist used in the treatment of refractory hypertension might have an important value.展开更多
Background Integrin-linked kinase （ILK） dysregulation is involved in the progression of diabetic nephropathy （DN）. The aim of this study was to investigate the effects of angiotensin II receptor blocker （ARB）, i...Background Integrin-linked kinase （ILK） dysregulation is involved in the progression of diabetic nephropathy （DN）. The aim of this study was to investigate the effects of angiotensin II receptor blocker （ARB）, irbesartan, on ILK expression and podocyte injury in DN.展开更多
目的观察厄贝沙坦对高血压病并阵发性心房颤动(简称房颤)患者左房功能的影响,探讨其对房颤预防及治疗的作用。方法104例高血压病合并阵发性房颤患者随机分治疗组和对照组。两组均给予基础降压治疗,治疗组除给予基础治疗外加用厄贝沙坦。...目的观察厄贝沙坦对高血压病并阵发性心房颤动(简称房颤)患者左房功能的影响,探讨其对房颤预防及治疗的作用。方法104例高血压病合并阵发性房颤患者随机分治疗组和对照组。两组均给予基础降压治疗,治疗组除给予基础治疗外加用厄贝沙坦。3个月后通过超声心动图观察左房功能。结果治疗后两组左房各项指标均明显改善,其中左房上下径、左房最大容积改善程度治疗组较对照组大(32.47±7.38 mm vs 38.47±6.47 mm;18.45±3.67 mm vs 30.56±3.68 mm,P<0.05或0.01)。治疗组的房颤发生次数显著低于对照组(1.2±0.36次vs2.1±0.42次,P<0.01)。结论厄贝沙坦能改善高血压病并阵发性房颤患者左房功能,降低房颤发生次数。展开更多
对130例高血压病患者及70名健康人的肾素(PRA)、血管紧张素Ⅱ(ATⅡ)、醛固酮及血浆心钠素(ANP)水平的检测及对其与中医辨证分型关系进行探讨。结果表明:(1)高血压患者基础 PRA 值低于健康人,而各型组间差异较大;阳亢型组 PRA、ATⅡ明显...对130例高血压病患者及70名健康人的肾素(PRA)、血管紧张素Ⅱ(ATⅡ)、醛固酮及血浆心钠素(ANP)水平的检测及对其与中医辨证分型关系进行探讨。结果表明:(1)高血压患者基础 PRA 值低于健康人,而各型组间差异较大;阳亢型组 PRA、ATⅡ明显高于对照组和阴虚阳亢、阴阳两虚组,组间差异非常显著(P<0.01～0.001)。说明PRA 及 ATⅡ在高血压中医分型中,可以作为区别各证型不同病理生理变化的客观指标之一。(2)高血压病患者 ANP 明显低于健康人(P<0.01),但三个中医证型组间无差异(P>0.05)。(3)对高血压患者严重心脑并发症的发生与中医证型及 PRA 水平的关系,各证型间转化与 PRA 水平关系作了初步探讨。展开更多
文摘Objective The study will explore effects of the autoantibodies against AT1 receptor and angiotensin Ⅱ on the refractory hypertension. Methods Seventy-seven patients (46 men and 31 women) with essential hypertension were divided into groups of refractory hypertension (RH) and hypertension (HT) according to the 1999 WHO-ISH Guidelines for the Management of Hypertension. Forty normotensives (22 men) were recruited as controls. The mean age was 54. 3±13 years old in RH group, 53. 5±9 years old in HT group and 51. 2±11. 9 years old in normotensives (NT) group. The mean blood pressure was 154. 2±9. 4/98. 4± 8. 2 mmHg in RH group and 130. 1±7. 6/80. 5±6. 7 mmHg in HT group after combination drug therapy of hypertension for 4 weeks. Blood pressure in NT group was 120. 8±11. 7/76. 4 ± 7. 2 mmHg. The epitope of the 2nd extracellular loops of AT1 receptor was synthesized and used as antigens to screen the autoantibodies by ELISA. Plasma angiotensin (Ang) II were examined by a radioimmunoassay. Results The autoantibodies against AT1 receptor were positive in 18 (46. 15 %) patients with RH, in 4 (10. 5 % ) hypertension and in 3 (7. 5 % ) normotensives, P < 0. 01. Ang Ⅱwas 57. 01±52. 63 pmol/L in patients with RH. Both the autoantibodies positive and the Ang Ⅱ increasing were 4 (10. 3 % ) cases, both normal were 7 (17. 9 % ) cases, the autoantibodies positive or Ang II increasing was all of 14 (35. 9 % ) cases (x2 = 0. 09, P>0. 05) . There was no relationship between the autoantibodies against AT1 receptor and the angiotensin Ⅱ in refractory hypertension. Conclusion The autoantibodies against AT1 receptor and Ang Ⅱ might be two independent factors in developing of refractory hypertension. The findings suggest that AT1 receptor an-tagnist used in the treatment of refractory hypertension might have an important value.
基金This study was supported by a grant from the National Natural Science Foundation of China （No. 30870953） to Prof. LIU Bi-cheng as PI.
文摘Background Integrin-linked kinase （ILK） dysregulation is involved in the progression of diabetic nephropathy （DN）. The aim of this study was to investigate the effects of angiotensin II receptor blocker （ARB）, irbesartan, on ILK expression and podocyte injury in DN.
文摘目的观察厄贝沙坦对高血压病并阵发性心房颤动(简称房颤)患者左房功能的影响,探讨其对房颤预防及治疗的作用。方法104例高血压病合并阵发性房颤患者随机分治疗组和对照组。两组均给予基础降压治疗,治疗组除给予基础治疗外加用厄贝沙坦。3个月后通过超声心动图观察左房功能。结果治疗后两组左房各项指标均明显改善,其中左房上下径、左房最大容积改善程度治疗组较对照组大(32.47±7.38 mm vs 38.47±6.47 mm;18.45±3.67 mm vs 30.56±3.68 mm,P<0.05或0.01)。治疗组的房颤发生次数显著低于对照组(1.2±0.36次vs2.1±0.42次,P<0.01)。结论厄贝沙坦能改善高血压病并阵发性房颤患者左房功能,降低房颤发生次数。
文摘对130例高血压病患者及70名健康人的肾素(PRA)、血管紧张素Ⅱ(ATⅡ)、醛固酮及血浆心钠素(ANP)水平的检测及对其与中医辨证分型关系进行探讨。结果表明:(1)高血压患者基础 PRA 值低于健康人,而各型组间差异较大;阳亢型组 PRA、ATⅡ明显高于对照组和阴虚阳亢、阴阳两虚组,组间差异非常显著(P<0.01～0.001)。说明PRA 及 ATⅡ在高血压中医分型中,可以作为区别各证型不同病理生理变化的客观指标之一。(2)高血压病患者 ANP 明显低于健康人(P<0.01),但三个中医证型组间无差异(P>0.05)。(3)对高血压患者严重心脑并发症的发生与中医证型及 PRA 水平的关系,各证型间转化与 PRA 水平关系作了初步探讨。
